Ultragenyx Pharmaceutical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
19analysts covering
FY Revenue (est.)
$758.3Mnext fiscal year
FY EPS (est.)
-$2.56next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenue Guidance Quarterly136MTarget: $730 million to $760 million
Crysvita Revenue Guidance Quarterly93MTarget: $500 million to $520 million
Dojolvi Revenue Guidance Quarterly18MTarget: $100 million to $110 million
Watch Items
- DTX401 (pariglasgene brecaparvovec) FDA PDUFA Action DateTrigger: August 23, 2026Action: Monitor FDA decision on the Biologics License Application (BLA) for the treatment of glycogen storage disease type Ia (GSDIa).
- UX111 (rebisufligene etisparvovec) FDA PDUFA Action DateTrigger: September 19, 2026Action: Monitor FDA decision on the resubmitted BLA for the treatment of Sanfilippo syndrome type A (MPS IIIA).
- GTX-102 (apazunersen) Phase 3 Aspire Study Data ReadoutTrigger: Second Half of 2026Action: Evaluate topline efficacy and safety data from the pivotal Phase 3 study in patients with Angelman syndrome.
Research as of 19 Jun 2026